Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-11
2011-10-11
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S420000, C514S090000, C548S500000, C564S013000, C544S313000
Reexamination Certificate
active
08034824
ABSTRACT:
The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.
REFERENCES:
patent: 2004 300147 (2004-10-01), None
patent: 98 35722 (1998-08-01), None
patent: WO 2004/060322 (2004-01-01), None
patent: 2004/060322 (2004-07-01), None
patent: 2004 060322 (2004-07-01), None
patent: 2004 105782 (2004-12-01), None
McCormick (Modulation of Rat Mammary Carcinogenesis by Indomethacin, Cancer research, vol. 45, Apr. 1985, pp. 1803-1808).
Harrison (Low-Dose Topical 5-Fluorouracil as Effective, Better Tolerated than Standard 5% cream: Presented at AAD, Doctor's Guide, http://docguide.com
ews/content.nsf/NewsPrint, pp. 1-2, 2002).
Jack (Adjuvant Therapy with 5-Fluorouracil for Breast Cancer of Likely Poor Prognosis: 15-Year Results of a Randomized Trial, Clinical Oncology, (1995).
Powis (Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients, Cancer Chemotherapy Pharmacology (1987) 20: pp. 219-222).
Ayumi Denda, “COX-2 and Cancer Prevention”, Journal of Clinical and Experimental Medicine, vol. 204, No. 1, 2003, pp. 10-19 (partial translation).
Makoto M. Taketo, “Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)”, Journal of the National Cancer Institute, vol. 90, No. 21, Nov. 4, 1998, pp. 1609-1620.
Yang Cao, et al.,“Many Actions of Cyclooxygenase-2 in Cellular Dynamics and in Cancer”, Journal of Cellular Physiology 190: (2002) pp. 279-286.
Marco E. Turini, et al., “Cyclooxygenase-2: A Therapeutic Target”, Annual Review Medicine, 2002, 53, pp. 35-57.
Ayumi Denda, et al., “Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, I-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide”, Carcinogenesis vol. 23, No. 2, 2002, pp. 245-256.
Yoshiko Ohtaka, et al., “Mastitis and Breast-feeding”, Perinatal Medicine, vol. 34, No. 9, Sep. 2004, pp. 1443-1445.
Yokohama Igaku, Journal of Yokohama Medical Association, 44, 1993, pp. 487-494.
Dermatology and Venereology, v(2), 65, 1951.
Inagi Toshio
Kanebako Makoto
Makino Kimiko
Terada Hiroshi
Toi Masakazu
Cruz Kathrien
Hui San-Ming
Kowa Co. Ltd.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Tokyo University of Science Educational Foundation Administrativ
LandOfFree
Iontophoretic preparation for treatment of breast cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Iontophoretic preparation for treatment of breast cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iontophoretic preparation for treatment of breast cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261921